Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs)

被引：0
|
作者：
Bader, Justin
McKean, Meredith
DeMars, Leslie Robbins
Lu, Yasong
Li, Mengyao
Dickson, Amy
Bennett, Gavin
Arroyo, Santiago
Fontana, Elisa
Carter, Louise
Ahnert, Jordi Rodon
Falchook, Gerald Steven
Xu, Hongmei
机构：
[1] Bicycle Therapeut, Cambridge, MA USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] BicycleTx Ltd, Cambridge, England
[4] Sarah Cannon Res Inst UK, London, England
[5] Univ Manchester, Manchester, England
[6] Christie NHS Fdn Trust, Manchester, England
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3088
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Optimizing the safety of antibody-drug conjugates for patients with solid tumours
    Tarantino, Paolo
    Ricciuti, Biagio
    Pradhan, Shan M.
    Tolaney, Sara M.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (08) : 558 - 576
  • [22] Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
    Donaghy, Heather
    MABS, 2016, 8 (04) : 659 - 671
  • [23] Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs)
    Mahmood, Iftekhar
    ANTIBODIES, 2021, 10 (04)
  • [24] Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
    Geraud, Arthur
    Gougis, Paul
    de Nonneville, Alexandre
    Beaufils, Mathilde
    Billon, Emilien
    Brisou, Gabriel
    Gravis, Gwenaelle
    Greillier, Laurent
    Guerin, Mathilde
    Mezni, Essia
    Mitry, Emmanuel
    Noel, Robin
    Pignon, Josephine
    Sabatier, Renaud
    Seguin, Lorene
    Spano, Jean-Philippe
    Vicier, Cecile
    Viret, Frederic
    Goncalves, Anthony
    Ciccolini, Joseph
    CANCER TREATMENT REVIEWS, 2025, 135
  • [25] Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer
    Cherifi, Francois
    Da Silva, Angelique
    Martins-Branco, Diogo
    Awada, Ahmad
    Nader-Marta, Guilherme
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (1-2) : 45 - 59
  • [26] Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates
    Kaempffe, Anna
    Dickgiesser, Stephan
    Rasche, Nicolas
    Paoletti, Andrea
    Bertotti, Elisa
    De Salve, Ilse
    Sirtori, Federico Riccardi
    Kellner, Roland
    Konning, Doreen
    Hecht, Stefan
    Anderl, Jan
    Kolmar, Harald
    Schroeter, Christian
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (12) : 3776 - 3785
  • [27] Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
    Deslandes, Antoine
    MABS, 2014, 6 (04) : 859 - 870
  • [28] Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates
    Li, Chunze
    Chen, Shang-Chiung
    Chen, Yuan
    Girish, Sandhya
    Kaagedal, Matts
    Lu, Dan
    Lu, Tong
    Samineni, Divya
    Jin, Jin Y.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S105 - S119
  • [29] Antibody-drug conjugates for ovarian cancer: current clinical development
    Stewart, Daphne
    Cristea, Mihaela
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2019, 31 (01) : 18 - 23
  • [30] Clinical perspective: Antibody-drug conjugates for the treatment of breast cancer
    Najminejad, Zohreh
    Dehghani, Fatemeh
    Mirzaei, Yousef
    Mer, Ali Hussein
    Saghi, Seyyed Amirreza
    Abdolvahab, Mohadeseh Haji
    Bagheri, Nader
    Meyfour, Anna
    Jafari, Ameneh
    Jahandideh, Saeed
    Gharibi, Tohid
    Amirkhani, Zahra
    Delam, Hamed
    Mashatan, Noushin
    Shahsavarani, Hosein
    Abdollahpour-Alitappeh, Meghdad
    MOLECULAR THERAPY, 2023, 31 (07) : 1874 - 1903
12345